Ernexa Therapeutics’ “Trojan Horse” stem cells can infiltrate ovarian tumors in mice, boosting T cell activity and leading to ...

AstraZeneca has produced some fresh data to back up its blockbuster ambitions for camizestrant, tying the oral SERD to a 56% ...

A large prospective, randomized clinical trial in patients with advanced breast cancer has found that the use of liquid ...

Antibody drugs that target the PD-1 and VEGF pathways are in the ASCO spotlight, while doctors wrestle with how to use a new ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...